Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer

Journal of the National Cancer Institute

Volumn 104, Issue 1, 2012, Pages 56-66

  Hall, Peter S ^a   McCabe, Christopher ^a,d   Stein, Robert C ^c   Cameron, David ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL;

ADULT; ARTICLE; BREAST CANCER; BUDGET; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EARLY CANCER; FEMALE; GENETIC SCREENING; GENOMICS; HUMAN; LYMPH NODE METASTASIS; MATHEMATICAL MODEL; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNCERTAINTY; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GENETIC TESTING; GENOME, HUMAN; GREAT BRITAIN; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MARKOV CHAINS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, ESTROGEN; RESEARCH DESIGN; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84855484712     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr484     Document Type: Article

References (44)

1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734. (Pubitemid 46622311)
3. National Institute for Health and Clinical Excellence. Early and Locally Advance Breast Cancer: Diagnosis and Treatment. 2009. http://guidance.nice.org. uk/CG80. Accessed July 22, 2011.
4. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9707):2055-2063.
5. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
6. Shankaran V, Bentrem D, Mulcahy M, Bennett C, Benson A. Economic implications of KRAS testing in metastatic colorectal cancer (mCRC). In: ASCO GI Cancers Symposium. San Francisco, CA; 2009. Abstract 298.
7. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther. 2010;14(6):375-384.
8. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst. 2009;101(17):1182-1192.
9. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ. 2006;333(7578):1118-1120.
10. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11(5):313-324.
11. Kondo M, Hoshi S, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat. 2008;112(1):175-187.
12. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. Cancer. 2007;109(6):1011-1018.
13. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist. 2010;15(5):457-465.
14. Schmidt C. Researchers consider value-of-information theory for selecting trials. J Natl Cancer Inst. 2010;102(3):144-146.
15. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338.
16. Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering long-term toxicity and patterns of recurrence. Pharmacoeconomics. 2011;29(5):415-432.
17. ATAC, Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer. 2003;98(9):1802-1810.
18. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101- 2109.
19. Office of National Statistics. Interim Life Tables for England and Wales 2006-2008. http://www.statistics.gov.uk. Actuary's Regent Street, Sheffield, S1 4DA, England. Department. UK Government [online]. Accessed December 7, 2010.
20. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-5671.
21. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177-1183.
22. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815.
23. Cowie MR, Wood DA, Coats AJS, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83(5):505-510.
24. NHS. National Health Service Executive. NHS Reference Costs 2008-2009. London, UK: Department of Health; 2010.
25. British National Formulary. British Medical Association and the Royal Pharmaceutical Society of Great Britain. London, UK: BMJ Publishing Group; 2011.
26. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer. 2007;97(4):479-485.
27. Lorgelly PK, Briggs AH, Wedel H, et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail. 2010;12(1):66-74.
28. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073-1081.
29. Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Economics. 2000;9(2):149-158.
30. Collett D. Modelling Survival Data in Medical Research. 2nd ed. London, UK: Chapman & Hall; 2003.
31. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London, UK; 2008. http://www.nice.org.uk/media/ B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed December 7, 2009.
32. R, Development, Core, Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. http://www.R-project.org. Accessed December 7, 2009.
33. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479-500.
34. Briggs A, Sculpher M, Dawson J, Fitzpatrick R, Murray D, Malchau H. The use of probabilistic decision models in technology assessment: the case of total hip replacement. Appl Health Econ Health Policy. 2004;3(2):79-89.
35. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Handbooks in Health Economic Evaluation. Oxford, UK: Oxford University Press; 2006.
36. Hall PS, McCabe C, Brown JM, Cameron DA. Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer. 2010;46(15):2674-2680.
37. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet. 2002;360(9334):711-715.
38. Cancer Research UK. Cancer Research UK CancerStats. http://info. cancerresearchuk.org/cancerstats. Accessed January 10, 2010.
39. Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst. 2007;99(7):506-515.
40. Bartlett JMS, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial [published online ahead of print March 2011]. J Clin Oncol. doi:10.1200/JCO.2010.30.3677.
41. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
42. Bartlett JM, Thomas J, Ross DT, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010;12(4):R47.
43. Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score - results from TransATAC. Clin Cancer Res. 2009;69(24) (suppl 3):74.
44. Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol. 2010;17(5):1406-1413.